Effects of C1 Inhibitor on Tissue Damage in a Porcine Model of Controlled Hemorrhage

ABSTRACT Activation of the complement system has been associated with tissue injury after hemorrhage and resuscitation in animals. We investigated whether administration of recombinant human C1-esterase inhibitor (rhC1-INH), a regulator of complement and contact activation systems, reduces tissue damage and cytokine release and improves metabolic acidosis in a porcine model of hemorrhagic shock. Male Yorkshire swine were assigned to experimental groups and subjected to controlled, isobaric hemorrhage to a target mean arterial pressure of 35 mmHg. Hypotension was maintained for 20 min followed by a bolus intravenous injection of rhC1-INH or vehicle; animals were then observed for 3 h. Blood chemistry and physiologic parameters were recorded. Lung and small intestine tissue samples were subjected to histopathologic evaluation and immunohistochemistry to determine the extent of injury and deposition of complement proteins. Cytokine levels and quantitative assessment of renal and hepatic function were measured via enzyme-linked immunosorbent assay and chemistry analyzer, respectively. Pharmacokinetics of rhC1-INH revealed dose proportionality for maximum concentration, half-life, and the time span in which the functional C1-INH level was greater than 1 IU/mL. Recombinant human C1-INH significantly reduced renal, intestinal, and lung tissue damage in a dose-dependent manner (100 and 250 IU/kg). In addition, rhC1-INH (250 IU/kg) markedly improved hemorrhage-induced metabolic acidosis and circulating tumor necrosis factor &agr;. The tissue-protective effects of rhC1-INH appear to be related to its ability to reduce tissue complement activation and deposition. Recombinant human C1-INH decreased tissue complement activation and deposition in hemorrhaged animals, improved metabolic acidosis, reduced circulating tumor necrosis factor &agr;, and attenuated tissue damage in this model. The observed beneficial effects of rhC1-INH treatment on tissue injury 20 min into severe hypotension present an attractive model of low-volume resuscitation, particularly in situations with a restrictive medical logistical footprint.

[1]  M. Huber-Lang,et al.  Molecular mechanisms of inflammation and tissue injury after major trauma-is complement the "bad guy"? , 2011, Journal of Biomedical Science.

[2]  John A. Jones,et al.  Severe controlled hemorrhage resuscitation with small volume poloxamer 188 in sedated miniature swine. , 2011, Resuscitation.

[3]  C. Moratz,et al.  Decay-accelerating factor mitigates controlled hemorrhage-instigated intestinal and lung tissue damage and hyperkalemia in swine. , 2011, The Journal of trauma.

[4]  John A. Jones,et al.  Development and resuscitation of a sedated, mature male miniature swine severe hemorrhage model. , 2011, The Journal of trauma.

[5]  Xinyue Lu,et al.  Decay-accelerating factor attenuates C-reactive protein-potentiated tissue injury after mesenteric ischemia/reperfusion. , 2011, The Journal of surgical research.

[6]  L. Koenderman,et al.  C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia , 2010, Critical care medicine.

[7]  John D Lambris,et al.  Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity , 2010, Innate immunity.

[8]  G. Tsokos,et al.  Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury , 2010, Journal of Neuroinflammation.

[9]  H. Alam,et al.  FLUID RESUSCITATION: PAST, PRESENT, AND THE FUTURE , 2010, Shock.

[10]  I. Tarkin,et al.  Patterns of mortality and causes of death in polytrauma patients--has anything changed? , 2009, Injury.

[11]  John D Lambris,et al.  Complement component C5a mediates hemorrhage-induced intestinal damage. , 2008, The Journal of surgical research.

[12]  Pedro Mejia,et al.  Biological activities of C1 inhibitor. , 2008, Molecular immunology.

[13]  H. Nakase,et al.  Protective effect of C1 esterase inhibitor on acute traumatic spinal cord injury in the rat , 2008, Neurological research.

[14]  C. Moratz,et al.  Decay-accelerating factor attenuates remote ischemia-reperfusion-initiated organ damage. , 2007, Clinical immunology.

[15]  M. Cohen,et al.  ROLE OF THE ALTERNATIVE PATHWAY IN THE EARLY COMPLEMENT ACTIVATION FOLLOWING MAJOR TRAUMA , 2007, Shock.

[16]  M. Handrigan,et al.  C5-blocking antibody reduces fluid requirements and improves responsiveness to fluid infusion in hemorrhagic shock managed with hypotensive resuscitation. , 2007, Journal of applied physiology.

[17]  G. Horstick,et al.  C1-ESTERASE INHIBITOR REVERSES FUNCTIONAL CONSEQUENCES OF SUPERIOR MESENTERIC ARTERY ISCHEMIA/REPERFUSION BY LIMITING REPERFUSION INJURY AND RESTORING MICROCIRCULATORY PERFUSION , 2007, Shock.

[18]  M. Fukuzawa,et al.  Features of a newly cloned pig C1 esterase inhibitor. , 2006, Journal of Biochemistry (Tokyo).

[19]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[20]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[21]  O. Götze,et al.  Complement Activation During Hemorrhagic Shock and Resuscitation in Swine , 2003, Shock.

[22]  B. Lämmle,et al.  C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction , 2002, Critical care medicine.

[23]  G. Horstick,et al.  C1‐Esterase‐Inhibitor Treatment at Early Reperfusion of Hemorrhagic Shock Reduces Mesentery Leukocyte Adhesion and Rolling , 2001, Microcirculation.

[24]  J. Younger,et al.  Detrimental effects of complement activation in hemorrhagic shock. , 2001, Journal of applied physiology.

[25]  B. Klosterhalfen,et al.  C1 inhibitor prevents capillary leakage after thermal trauma , 2000, Critical care medicine.

[26]  E. Strauss,et al.  Complement and contact activation in term neonates after fetal acidosis , 1998, Archives of disease in childhood. Fetal and neonatal edition.

[27]  J. Köhl,et al.  Circulating complement proteins in multiple trauma patients--correlation with injury severity, development of sepsis, and outcome. , 1997, Critical care medicine.

[28]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[29]  W. Rodkey,et al.  Splenic red cell sequestration and blood volume measurements in conscious pigs. , 1985, The American journal of physiology.

[30]  Hannon Jp.  Blood acid-base curve nomogram for immature domestic pigs. , 1983 .

[31]  W. Sibbald,et al.  Shock in the emergency department. , 1976, JACEP.

[32]  N. Stocchetti,et al.  Neuroprotective effect of C1-inhibitor following traumatic brain injury in mice. , 2008, Acta neurochirurgica. Supplement.

[33]  C. Hack,et al.  Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. , 1993, Blood.

[34]  J. P. Hannon.  Blood acid-base curve nomogram for immature domestic pigs. , 1983, American journal of veterinary research.